Details of the Drug

General Information of Drug (ID: DMMOFHT)

Drug Name
Pirprofen
Synonyms
Pirprofen; Rengasil; 31793-07-4; Pirprofenum [INN-Latin]; Pirprofene [INN-French]; Pirprofeno [INN-Spanish]; SU-21524; EINECS 250-805-8; BRN 1686438; SU 21524; Hydratropic acid, 3-chloro-4-(3-pyrrolin-1-yl)-; 3-CHLORO-4-(3-PYRROLIN-1-YL)HYDRATROPIC ACID; C13H14ClNO2; Pirprofenum; Pirprofeno; Pirprofene; Benzeneacetic acid, 3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)-alpha-methyl-; Pirprofen [USAN:INN:BAN]; Pirprofen [USAN:BAN:INN]; pirprofen[usan:ban:inn]; Pirprofen (USAN/INN); AC1Q5RRJ; AC1L1UQD; SCHEMBL24311; 5-20-04-00276 (Beilstei
Indication
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [1]
ATC Code
M01AE08: Pirprofen
M01AE: Propionic acid derivatives
M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M: MUSCULO-SKELETAL SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 251.71
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 45.4 micromolar/kg/day [3]
Chemical Identifiers
Formula
C13H14ClNO2
IUPAC Name
2-[3-chloro-4-(2,5-dihydropyrrol-1-yl)phenyl]propanoic acid
Canonical SMILES
CC(C1=CC(=C(C=C1)N2CC=CC2)Cl)C(=O)O
InChI
InChI=1S/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)
InChIKey
PIDSZXPFGCURGN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
35935
ChEBI ID
CHEBI:135028
CAS Number
31793-07-4
UNII
T7KN291890
DrugBank ID
DB13722
TTD ID
D0S9ET
INTEDE ID
DR1304

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 1A1 (UGT1A1)
Main DME 		DEYGVN4 UD11_HUMAN Substrate [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [5]
Bone morphogenetic protein 6 (BMP6) OT9WN536 BMP6_HUMAN Gene/Protein Processing [5]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Gene/Protein Processing [5]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [5]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Gene/Protein Processing [5]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Gene/Protein Processing [5]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Gene/Protein Processing [5]
PTB-containing, cubilin and LRP1-interacting protein (PID1) OT5YJ7FI PCLI1_HUMAN Gene/Protein Processing [5]
Tumor necrosis factor-inducible gene 6 protein (TNFAIP6) OT1SLUZH TSG6_HUMAN Gene/Protein Processing [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
4 Glucuronidation of 2-arylpropionic acids pirprofen, flurbiprofen, and ibuprofen by liver microsomes. Drug Metab Dispos. 1990 Sep-Oct;18(5):692-7.
5 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.